Esophageal Cancer Pipeline constitutes 80+ key companies continuously working towards developing 100+ Esophageal Cancer treatment therapies, analyzes DelveInsight.
Esophageal Cancer Overview:
Esophageal cancer is a serious and often deadly disease that forms in the esophagus—the tube that carries food from the throat to the stomach. Though not very common, it has a high mortality rate due to frequent late-stage diagnosis. The two primary types are squamous cell carcinoma, which originates in the lining of the esophagus, and adenocarcinoma, which typically arises in the lower esophagus from glandular cells. Early symptoms often mimic milder conditions, leading to delayed detection. Common signs include difficulty swallowing, unexplained weight loss, chest pain, persistent cough, hoarseness, and food regurgitation. In advanced cases, bleeding, anemia, or black stools may occur.
While the exact cause is unclear, known risk factors include chronic GERD, Barrett’s esophagus, smoking, excessive alcohol consumption, obesity, and a poor diet. These contribute to genetic mutations and cellular damage that promote tumor growth.
Diagnosis involves a combination of endoscopy, biopsies, and imaging tests like CT, PET scans, and endoscopic ultrasound to confirm cancer and determine its type and spread. Early detection is crucial for better outcomes.
Request for a detailed insights report on Esophageal Cancer pipeline insights
"Esophageal Cancer Pipeline Insight 2025" report by DelveInsight provides a comprehensive analysis of the ongoing clinical development activities and growth prospects across the Esophageal Cancer Therapeutics Market.
Key Takeaways from the Esophageal Cancer Pipeline Report
-
DelveInsight’s Esophageal Cancer pipeline report depicts a robust space with 70+ active players working to develop 75+ pipeline therapies for Esophageal Cancer treatment.
-
In January 2025, RNT Health Insights, a health-tech startup based in Chandigarh, received its second Breakthrough Device Designation from the US FDA for its esophageal cancer detection tool. This AI-powered tool assists gastroenterologists in identifying both early and advanced stages of esophageal cancer during white-light upper GI endoscopy procedures.
-
Key Esophageal Cancer companies such as OncoTherapy Science, Inc., Shionogi & Co., Oncolys BioPharma Inc., Lyvgen Biopharma, Adlai Nortye Biopharma, NovaRock Biotherapeutics, Genmab, Genentech, Jiangsu HengRui Medicine, Taiho Pharmaceutical, Mirati Therapeutics, Boehringer Ingelheim, Suzhou Zelgen Biopharmaceuticals, Active Biotech, NeoTX Therapeutics, Rakuten Medical, HLB, CDR-Life, Schrodinger, BioSyngen, Guangzhou Bio-gene Technology, GO Therapeutics, and others are evaluating new drugs for Esophageal Cancer to improve the treatment landscape.
-
Promising Esophageal Cancer pipeline therapies in various stages of development include S-588410, Telomelysin, LVGN-6051, AN-0025, and others.
Esophageal Cancer Pipeline Analysis
The report provides insights into:
-
The report provides detailed insights into the key companies that are developing therapies in the Esophageal Cancer Market.
-
The report also evaluates different therapeutic candidates segmented into early-stage, mid-stage, and late-stage of development for Esophageal Cancer treatment.
-
It analyzes the key companies involved in targeted therapeutics development with respective active and inactive (dormant or discontinued) projects.
-
It navigates the emerging drugs under development based on the stage of development, route of administration, target receptor, monotherapy or combination therapy, a different mechanism of action, and molecular type.
-
Detailed analysis of collaborations (company-company collaborations and company-academia collaborations), licensing agreement, and financing details for future advancement of the Esophageal Cancer market.
Download our free sample page report on Esophageal Cancer pipeline insights
Esophageal Cancer Emerging Drugs
-
S-588410: OncoTherapy Science, Inc. /Shionogi & Co.
-
Telomelysin: Oncolys BioPharma Inc
-
LVGN-6051: Lyvgen Biopharma
-
AN-0025: Adlai Nortye Biopharma
Esophageal Cancer Companies
More than 80 major companies are actively developing treatments for esophageal cancer. Among them, OncoTherapy Science, Inc. and Shionogi & Co. have drug candidates that are currently in the most advanced stage of development—Phase III clinical trials.
DelveInsight’s report covers around 100+ products under different phases of clinical development like
-
Late stage products (Phase III)
-
Mid-stage products (Phase II)
-
Early-stage product (Phase I) along with the details of
-
Pre-clinical and Discovery stage candidates
-
Discontinued & Inactive candidates
Esophageal Cancer pipeline report provides the therapeutic assessment of the pipeline drugs by the Route of Administration. Products have been categorized under various ROAs such as
-
Intravenous
-
Subcutaneous
-
Oral
-
Intramuscular
Esophageal Cancer Products have been categorized under various Molecule types such as
-
Monoclonal antibody
-
Small molecule
-
Peptide
Download Sample Pages to Get an in-depth Assessment of the Emerging Esophageal Cancer Therapies and Key Companies: Esophageal Cancer Clinical Trials and advancements
Esophageal Cancer Pipeline Therapeutic Assessment
• Esophageal Cancer Assessment by Product Type
• Esophageal Cancer By Stage
• Esophageal Cancer Assessment by Route of Administration
• Esophageal Cancer Assessment by Molecule Type
Download Esophageal Cancer Sample report to know in detail about the Esophageal Cancer treatment market @ Esophageal Cancer Therapeutic Assessment
Table of Content
1. Report Introduction
2. Executive Summary
3. Esophageal Cancer Current Treatment Patterns
4. Esophageal Cancer - DelveInsight's Analytical Perspective
5. Therapeutic Assessment
6. Esophageal Cancer Late-Stage Products (Phase-III)
7. Esophageal Cancer Mid-Stage Products (Phase-II)
8. Early Stage Products (Phase-I)
9. Pre-clinical Products and Discovery Stage Products
10. Inactive Products
11. Dormant Products
12. Esophageal Cancer Discontinued Products
13. Esophageal Cancer Product Profiles
14. Esophageal Cancer Key Companies
15. Esophageal Cancer Key Products
16. Dormant and Discontinued Products
17. Esophageal Cancer Unmet Needs
18. Esophageal Cancer Future Perspectives
19. Esophageal Cancer Analyst Review
20. Appendix
21. Report Methodology
Request the Sample PDF to Get Detailed Insights About the Esophageal Cancer Pipeline Reports Offerings
Media Contact
Company Name: DelveInsight Business Research LLP
Contact Person: Kritika Rehani
Email:Send Email
Phone: +14699457679
Address:304 S. Jones Blvd #2432
City: Las Vegas
State: Nevada
Country: United States
Website: https://www.delveinsight.com/
